The pluripotential effects of hypolipidemic treatment for polycystic ovarysyndrome (PCOS): Dyslipidemia, cardiovascular risk factors and beyond

Current Pharmaceutical Design

Volumn 17, Issue 9, 2011, Pages 908-921

  Economou, Frangiskos ^a   Xyrafis, Xenofon ^a   Christakou, Charikleia ^a   Diamanti Kandarakis, Evanthia ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Antiandrogens; Dyslipidemia; Insulin sensitizers; Polycystic ovary syndrome; Statins

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIANDROGEN; ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; CLOMIFENE CITRATE; COMPACTIN; FLUTAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN SENSITIZING AGENT; LIPID; LOW DENSITY LIPOPROTEIN; METFORMIN; OMEGA 3 FATTY ACID; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SIMVASTATIN; SPIRONOLACTONE; TETRAHYDROLIPSTATIN; TROGLITAZONE;

ADD ON THERAPY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG EFFECT; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENDOCRINE DISEASE; ENVIRONMENTAL FACTOR; GENE EXPRESSION; GLUCOSE TOLERANCE; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPOLIPEMIA; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER FAILURE; METABOLIC SYNDROME X; MOOD DISORDER; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; PREVALENCE; PRIORITY JOURNAL; REPRODUCTION; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; POLYCYSTIC OVARY SYNDROME; RISK FACTORS;

EID: 79958210053     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211795428821     Document Type: Article

References (194)

1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey ofthe polycystic ovary syndrome in the Greek island of Lesbos: hormonaland metabolic profile. J Clin Endocrinol Metab 1999;84(11): 4006-11.
2. Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of thepolycystic ovary syndrome in unselected Caucasian women fromSpain. J Clin Endocrinol Metab 2000; 85(7): 2434-38.
3. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndromein an unselected population. J Clin Endocrinol Metab 2004; 89(6):2745-49.
4. Zawadki JK, Dunaif A. Diagnostic criteria for polycystic ovarysyndrome: towards a rational approach. In: Dunaif A, Givens JR,Haseltine FP, Merriam GR, Eds. Polycystic ovary syndrome. Boston:Blackwell Scientific Publications 1992; pp 377-84
5. The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus WorkshopGroup Revised 2003 consensus on diagnostic criteria andlong-term health risks related to polycystic ovary syndrome(PCOS). Hum Reprod 2004; 19: 41-47
6. Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteriafor defining polycystic ovary syndrome as a predominantly hyperandrogenicsyndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006; 91(11): 4237-45
7. Diamanti-Kandarakis E, Panidis D. Unraveling the phenotypic mapof polycystic ovary syndrome (PCOS): a prospective study of 634women with PCOS. Clin Endocrinol (Oxf), 2007; 67(5): 735-42.
8. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors ofdyslipidemia in women with polycystic ovary syndrome. Am JMed 2001; 111: 607-613
9. Carmina E. Cardiovascular risk and events in polycystic ovarysyndrome. Climateric 2009; 12 (Suppl 1): s22-25
10. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors forcoronary artery disease in lean and obese women with the polycysticovary syndrome. Clin Endocrinol (Oxf) 1992; 37: 119-125.
11. Talbott E, Clerici A, Berga SL, et al. Adverse lipid and coronaryheart disease risk profiles in young women with polycystic ovarysyndrome: results of a case-control study. J Clin Epidemiol 1998;51: 415-422
12. Carmina E, Legro RS, Stamets K, Lowell J, Lobo RA. Differencein body weight between American and Italian women with polycysticovary syndrome: influence of the diet. Hum Reprod 2003;18(11): 2289-93.
13. Legro RS, Spielman R, Urbanek M, Driscoll D, Strauss JF 3rd, Dunaif A. Phenotype and genotype in polycystic ovary syndrome. Recent Prog Horm Res. 1998; 53: p.217-56.
14. Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulationand hirsutism in the polycystic ovary syndrome: a multicenter,double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001; 86: 1626-32
15. Yildirim B, Sabir N, Kaleli B. Relation of intra-abdominal fatdistribution to metabolic disorders in nonobese patients with polycysticovary syndrome. Fertil Steril 2003; 79(6): 1358-64.
16. Mittelman SD, Van Citters GW, Kirkman EL, Bergman RN. Extremeinsulin resistance of the central adipose depot in vivo. Diabetes 2002; 51(3): 755-61.
17. Bergman RN, Van Citters GW, Mittelman SD, et al. M. Central role of the adipocyte in the metabolic syndrome. J Investig Med 2001; 49(1): 119-26.
18. Bjorntorp P. Metabolic abnormalities in visceral obesity. Ann. Med 1992; 24: 3-5
19. Ek I, Arner P, Rydén M, et al. A unique defect in the regulation ofvisceral fat cell lipolysis in the polycystic ovary syndrome as anearly link to insulin resistance. Diabetes 2002; 51(2): 484-92.
20. Carmina E, Lobo RA. Use of fasting blood to assess the prevalenceof insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2004; 82: 661-65.
21. De Ugarte CM, Bartolucci AA, Azziz R. Prevalence of insulinresistance in the polycystic ovary syndrome using the homeostasismodel assessment. Fertil Steril 2005; 83: 1454-60
22. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheralinsulin resistance, independent of obesity, in polycysticovary syndrome. Diabetes 1989; 38: 1165-74
23. Dunaif A, Xia J, Book C B, Schenker E, Tang Z. Excessive insulinreceptor serine phosphorylation in cultured fibroblasts and in skeletalmuscle. A potential mechanism for insulin resistance in thepolycystic ovary syndrome. J Clin Invest 1995; 96(2): 801-810
24. Corbould A, Zhao H, Mirzoeva S, Aird F, Dunaif A. Enhancedmitogenic signaling in skeletal muscle of women with polycysticovary syndrome. Diabetes 2006; 55: 751-9.
25. Cortón M, Botella-Carretero JI, Benguría A, et al. Differential geneexpression profile in omental adipose tissue in women with polycysticovary syndrome. J Clin Endocrinol Metab 2007; 92(1): 328-37.
26. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors ofdyslipidemia in women with polycystic ovary syndrome. Am JMed. 2001; 11(8): 607-13.
27. Wetterau JR, Lin MC, Jamil H. Microsomal triglyceride transferprotein. Biochim Biophys Acta 1997; 1345(2): 136-50.
28. Au WS, Kung HF, Lin MC. Regulation of microsomal triglyceridetransfer protein gene by insulin in HepG2 cells: roles of MAPKerkand MAPKp38. Diabetes 2003; 52(5): 1073-80.
29. Taghibiglou C, Carpentier A, Van Iderstine SC, et al. Mechanismsof hepatic very low density lipoprotein overproduction in insulinresistance. Evidence for enhanced lipoprotein assembly, reducedintracellular ApoB degradation, and increased microsomal triglyceridetransfer protein in a fructose-fed hamster model J Biol Chem 2000; 275(12): 8416-25.
30. von Eckardstein, A. Androgens, cardiovascular risk factors, andatherosclerosis. Nieschlag E, Behre, H M, Eds. In Testosterone:Action, Deficiency, Substitution (2nd edn), Springer 1998; pp. 229-258
31. Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, SiscovickDS. Intramuscular testosterone esters and plasma lipids in hypogonadalmen: a meta-analysis. Am J Med 2001; 111(4): 261-9.
32. Langer C, Gansz B, Goepfert C, et al. Testosterone up-regulatesscavenger receptor BI and stimulates cholesterol efflux frommacrophages. Biochem Biophys Res Commun 2002; 296(5): 1051-7.
33. Herbst KL, Amory JK, Brunzell JD, Chansky HA, Bremner WJ.Testosterone administration to men increases hepatic lipase activityand decreases HDL and LDL size in 3 wk. Am J Physiol EndocrinolMetab 2003; 284(6): E1112-8.
34. Tan KC, Shiu SW, Kung AW. Alterations in hepatic lipase andlipoprotein subfractions with transdermal testosterone replacementtherapy. Clin Endocrinol (Oxf). 1999; 51(6): 765-9.
35. Pirwany IR, Fleming R, Greer IA, Packard CJ, Sattar N. Lipids andlipoprotein subfractions in women with PCOS: relationship tometabolic and endocrine parameters. Clin Endocrinol (Oxf) 2001;54(4): 447-53.
36. Croston GE, Milan LB, Marschke KB, Reichman M, Briggs MR.Androgen receptor-mediated antagonism of estrogen-dependentlow density lipoprotein receptor transcription in cultured hepatocytes. Endocrinology 1997; 138(9): 3779-86.
37. Anderson LA, McTernan PG, Harte AL, Barnett AH, Kumar S.The regulation of HSL and LPL expression by DHT and flutamidein human subcutaneous adipose tissue. Diabetes Obes Metab 2002;4(3): 209-13.
38. Iverius PH, Brunzell JD. Relationship between lipoprotein lipaseactivity and plasma sex steroid level in obese women. J Clin Invest.1988; 82(3): 1106-12.
39. Lithell H, Nillius SJ, Bergh T, Selinus I. Metabolic profile in obesewomen with the polycystic ovary syndrome. Int J Obes 1987; 11(1):1-8.
40. Corbould A. Chronic testosterone treatment induces selective insulinresistance in subcutaneous adipocytes of women. J. Endocrinol 2007; 192: 585-94
41. Bandyopadhyay G, Sajan MP, Kanoh Y, et al. PKC-zeta mediatesinsulin effects on glucose transport in cultured preadipocytederivedhuman adipocytes. J Clin Endocrinol Metab 2002; 87(2):716-23.
42. Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab 2007; 18: 280-85.
43. Essah PA, Nestler JE, Carmina E. Differences in dyslipidemiabetween American and Italian women with polycystic ovary syndrome. J Endocrinol Invest 2008; 31: 35-41.
44. Valkenburg O, Steegers-Theunissen RP, Smedts HP, et al. A moreatherogenic serum lipoprotein profile is present in women withpolycystic ovary syndrome: a case-control study. J Clin EndocrinolMetab 2008; 93: 470-76.
45. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors forcoronary artery disease in lean and obese women with the polycysticovary syndrome. Clin Endocrinol (Oxf) 1992; 37(2): 119-25.
46. Third Report of the National Cholesterol Education Program(NCEP) Expert panel on detection, evaluation, and treatment ofhigh blood cholesterol in adults (Adult Treatment Panel III) finalreport. Circulation 2002; 106: 3143-421
47. Berneis K, Rizzo M, Lazzarini V, Fruzzetti F, Carmina E. Atherogeniclipoprotein phenotype and low-density lipoproteins size andsubclasses in women with polycystic ovary syndrome. J Clin EndocrinolMetab 2007; 92(1): 186-9.
48. Dejager S, Pichard C, Giral P, et al. Smaller LDL particle size inwomen with polycystic ovary syndrome compared to controls. ClinEndocrinol (Oxf) 2001; 54(4): 455-62.
49. Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycysticovary syndrome: systematic review and meta-analysis. FertilSteril 2011; 95(3): 1073-1079.
50. Rizzo M, Longo RA, Guastella E, Rini GB, Carmina E. Assessingcardiovascular risk in Mediterranean women with Polycystic OvarySyndrome. J Endocrinol Invest. 2010 Oct 15. [Epub ahead of print]
51. Rizzo M, Berneis K, Hersberger M, et al. Milder forms of atherogenicdyslipidemia in ovulatory versus anovulatory polycysticovary syndrome phenotype. Hum Reprod 2009; 24: 2286-92.
52. Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment ofcardiovascular risk and prevention of cardiovascular disease inwomen with the polycystic ovary syndrome: a consensus statementby the Androgen Excess and Polycystic Ovary Syndrome (AEPCOS)Society. J Clin Endocrinol Metab 2010; 95(5): 2038-49.
53. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, ImperialJ. Prevalence of impaired glucose tolerance and diabetes in womenwith polycystic ovary syndrome. Diabetes Care 1999; 22: 141-46.
54. O'Meara NM, Blackman JD, Ehrmann DA, et al. Defects in betacellfunction in functional ovarian hyperandrogenism. J Clin EndocrinolMetab 1993; 76(5): 1241-7.
55. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL,Polonsky KS. Insulin secretory defects in polycystic ovary syndrome.Relationship to insulin sensitivity and family history ofnon-insulindependent diabetes mellitus. J Clin Invest 1995; 96:520-7
56. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in womenwith polycystic ovary syndrome. Hum Reprod Update 2006; 12:673-683.
57. Barr ELM, Magliano DJ, Zimmet PZ, et al. AusDiab 2005: TheAustralian Diabetes, Obesity and Lifestyle Study. Melbourne, Australia:International Diabetes Institute; 2006
58. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in theincidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
59. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a newworldwide definition. Lancet 2005; 366: 1059-1062.
60. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. Prevalence and predictors of metabolic syndrome inwomen with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 48-53
61. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence andcharacteristics of the metabolic syndrome in women with polycysticovary syndrome. J Clin Endocrinol Metab 2005; 90: 1929-35.
62. Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA. Metabolicsyndrome in polycystic ovary syndrome (PCOS): lower prevalencein southern Italy than in the USA and the influence of criteria forthe diagnosis of PCOS. Eur J Endocrinol 2006; 154: 141-5.
63. Alvarez-Blasco F, Botella-Carretero JI, San Millán JL, Escobar-Morreale HF Prevalence and characteristics of the polycystic ovarysyndrome in overweight and obese women. Arch Intern Med 2006;166: 2081-86
64. Cascella T, Palomba S, De Sio I, et al. Visceral fat is associatedwith cardiovascular risk in women with polycystic ovary syndrome. Hum Reprod 2008; 23: 153-59
65. Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increasedendothelin-1 levels in women with polycystic ovary syndrome andthe beneficial effect of metformin therapy. J Clin Endocrinol Metab 2001; 86: 4666-4673
66. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychologicalfactors on the pathogenesis of cardiovascular disease and implicationsfor therapy. Circulation 1999; 99: 2192-217.
67. Ounpuu S, Negassa A, Yusuf S. INTER-HEART: A global studyof risk factors for acute myocardial infarction. Am Heart J 2001;141: 711-21.
68. Jones GL, Hall JM, Balen AH, Ledger WL. Health-related qualityof life measurement in women with polycystic ovary syndrome: asystematic review. Hum Reprod Update 2008; 14: 15-25
69. Bishop SC, Basch S, FutterweitW. Polycystic ovary syndrome,depression and affective disorders. Endocr Pract 2009; 15: 475-482.
70. Hollinrake E, Abreu A, Maifeld M, Van Voorhis BJ, Dokras A.Increased risk of depressive disorders in women with polycysticovary syndrome. Fertil Steril 2007; 87: 1369-76.
71. Weiner CL, Primeau M, Ehrmann DA. Androgens and mood dysfunctionin women: comparison of women with polycystic ovariansyndrome to healthy controls. Psychosom Med 2004; 66: 356-62.
72. Dixon JB, Dixon ME, O'Brien PE. Depression in association withsevere obesity. Arch Intern Med 2003; 163: 2058-65.
73. Barth JH, Catalan J, Cherry CA, Day A. Psychological morbidity inwomen referred for treatment of hirsutism. J Psychosom Res 1993;37: 615-19.
74. Sonino N, Fava GA, Mani E, Belluardo P, Boscaro M. Quality oflife of hirsute women. Postgrad Med J 1993; 69: 186-189.
75. Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of life in acne: a comparison with generalmedical conditions using generic questionnaires. Br J Dermatol 1999; 140 (4): 672-76
76. Downey J, Yingling S, McKinney M, Husami N, Jewelewicz R, Maidman J. Mood disorders, psychiatric symptoms, and distress inwomen presenting for infertility evaluation. Fertil Steril 1989; 52:425-32.
77. Paulson JD, Haarmann BS, Salerno RL, Asmar P. An investigationof the relationship between emotional maladjustment and infertility. Fertil Steril 1988; 49: 258-62.
78. Moran L, Gibson-Helm M, Teede H, Deeks A. Polycystic ovarysyndrome: a biopsychosocial understanding in young women toimprove knowledge and treatment options. J Psychosom ObstetGynaecol 2010; 31(1): 24-31.
79. Simon A, Gariepy J, Chironi G, Megnien JL, Levenson J. Intimamediathickness: a new tool for diagnosis and treatment of cardiovascularrisk. J Hypertens 2002; 20: 159-69.
80. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE, Kuller LH. Evidence for associationbetween polycystic ovary syndrome and premature carotid atherosclerosisin middle-aged women. Arterioscler Thromb Vasc Biol 2000; 20: 2414-21.
81. Gambineri A, Pasquali R. Insulin resistance, obesity and metabolicsyndrome in polycystic ovary syndrome. Endocrinol Nutr 2006; 53(Suppl 1): s49-55.
82. Luque-Ramírez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF. Androgen excess is associated with the increasedcarotid intima-media thickness observed in young womenwith polycystic ovary syndrome. Hum Reprod 2007; 22: 3197-203.
83. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy 2nd PF, Fitzpatrick LA. Prevalence and predictors of coronary arterycalcification in women with polycystic ovary syndrome. J Clin EndocrinolMetab 2003; 88: 2562-68.
84. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS. Evidence for an association betweenmetabolic cardiovascular syndrome and coronary and aortic calcificationamong women with polycystic ovary syndrome. J Clin EndocrinolMetab 2004; 89: 5454-61.
85. Arad Y, Spadaro LA, Goodman K, Newstein D, Guerci AD. Predictionof coronary events with electron beam computed tomography. J Am Coll Cardol 2000; 36: 1253-60.
86. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospectivestudy of C-reactive protein and the risk of future cardiovascularevents among apparently healthy women. Circulation 1998; 98:731-33.
87. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive proteinand other markers of inflammation in the prediction of cardiovasculardisease in women. N Engl J Med 2000; 342: 836-43.
88. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, themetabolic syndrome, and risk of incident cardiovascular events: an8-year follow- up of 14719 initially healthy American women. Circulation 2003; 107: 391-97.
89. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, et al. Indicesof low-grade chronic inflammation in polycystic ovary syndromeand the beneficial effect of metformin. Human Reprod 2006; 21:1426-31.
90. Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B.Central fat excess in polycystic ovary syndrome: relation to lowgradeinflammation and insulin resistance. J Clin Endocrinol Metabol 2005; 90: 6014-21.
91. Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA. Phenotypicvariation in hyperandrogenic women influences the findings of abnormalmetabolic and cardiovascular risk parameters. J Clin EndocrinolMetabol 2005; 90: 2545-49.
92. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortalityof women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998; 51: 581-586
93. Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal womenwith a history of irregular menses and elevated androgen measurementsat high risk for worsening cardiovascular event-free survival:results from the National Institutes of Health-National Heart, Lung,and Blood Institute sponsored Women's Ischemia SyndromeEvaluation. J Clin Endocrinol Metab 2008; 93: 1276-1284
94. Krentz AJ, von Mühlen D, Barrett-Connor E. Searching for polycysticovary syndrome in postmenopausal women: evidence of adose-effect association with prevalent cardiovascular disease. Menopause 2007; 14: 284-92.
95. Azevedo GD, Duarte JM, Souza MO, Costa-E-Silva TD, SoaresEM, Maranhão TM. Menstrual cycle irregularity as a marker ofcardiovascular risk factors at postmenopausal years. Arq Bras EndocrinolMetabol 2006; 50: 876-83
96. Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulinsensitivity but persistently increased early insulin secretion afterweight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1995; 80: 2586-2593.
97. Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatmentof obesity in polycystic ovary syndrome: a position statementof the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril 2009; 92(6): 1966-82.
98. Andersen P, Seljeflot I, Abdelnoor M, et al. Increased insulin sensitivityand fibrinolytic capacity after dietary intervention in obesewomen with polycystic ovary syndrome. Metab Clin Exp 1995; 44:611-616.
99. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductivepotential by lifestyle modification in obese polycysticovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999; 84: 1470-1474.
100. Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement inendocrine and ovarian function during dietary treatment of obesewomen with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992; 36: 105-111.
101. Diamanti-Kandarakis E, Katsikis I, Piperi C, Alexandraki K, Panidis D. Effect of long-term orlistat treatment on serum levels of advancedglycation end-products in women with polycystic ovarysyndrome. Clin Endocrinol (Oxf) 2007; 66: 103-109.
102. Jayagopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL. Orlistat is as beneficial as metformin in the treatment of polycysticovarian syndrome. J Clin Endocrinol Metab 2005; 90: 729-733.
103. Panidis D, Farmakiotis D, Rousso D, Kourtis A, Katsikis I, Krassas G. Obesity, weight loss, and the polycystic ovary syndrome: effectof treatment with diet and orlistat for 24 weeks on insulin resistanceand androgen levels. Fertil Steril 2008; 89: 899-906.
104. Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicilliumcitrinium. J Antibiot (Tokyo). 1976; 29(12): 1346-8.
105. Endo A. The origin of the statins. 2004. Atheroscler Suppl. 2004;5(3): 125-30.
106. Zhang FL, Casey PJ. Protein prenylation: molecular mechanismand functional consequences. Ann Rev Biochem 1996; 65: 241-69.
107. Bouterfa HL, Sattelmeyer V, Czub S, Vordermark D, Roosen K, Tonn JC Inhibition of Ras farnesylation by lovastatin leads todownregulation of proliferation and migration in primary culturedhuman glioblastoma cells. Anticancer Res 2000; 20: 2761-71.
108. Kodaman PH, Duleba AJ. Statins in the treatment of polycysticovary syndrome. Semin Reprod Med 2008; 26(1): 127-38.
109. Wassmann S, Laufs U, Muller K, et al. Cellular antioxidant effectsof atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22: 300-5.
110. Carlberg M, Dricu A, Blegen H, et al. Mevalonic acid is limitingfor N-linked glycosylation and translocation of the insulin-likegrowth factor-I receptor to the cell surface. Evidence for a new linkbetween 3-hydroxy-3-methylglutaryl coenzyme A reductase andcell growth. J Biol Chem 1996; 271: 17453-62.
111. Siddals KW, Marshman E, Westwood 4M, Gibson JM. Abrogationof insulin-like growth factor-I (IGF-I) and insulin action by mevalonicacid depletion; synergy between protein prenylation and receptorglycosylation pathways. J Biol Chem 2004; 279: 38353-59
112. Izquierdo D, Foyouzi N, Kwintkiewicz J, Duleba AJ. Mevastatininhibits ovarian theca-interstitial cell proliferation and steroidogenesis. Fertil Steril 2004; 82: 1193-97.
113. Dobs AS, Schrott H, Davidson MH, et al. Effects of high-dosesimvastatin on adrenal and gonadal steroidogenesis in men withhypercholesterolemia. Metabolism: Clinical & Experimental 2000; 49: 1234-38.
114. Kwintkiewicz J, Foyouzi N, Piotrowski P, Rzepczynska I, Duleba AJ. Mevastatin inhibits proliferation of rat ovarian theca-interstitialcells by blocking the mitogen activated protein kinase pathway. Fertil Steril 2006; 86: 1053-58.
115. Sokalska A, Piotrowski PC, Rzepczynska IJ, Cress A, Duleba AJ. Statins inhibit growth of human theca-interstitial cells in PCOS andnon-PCOS tissues independently of cholesterol availability. J ClinEndocrinol Metab 2010; 95(12): 5390-94.
116. Duleba AJ, Banaszewska B, Spaczynski RZ, Pawelczyk L. Simvastatinimproves biochemical parameters in women with polycysticovary syndrome: results of a prospective, randomized trial. FertilSteril 2006; 85(4): 996-1001.
117. Banaszewska B, Pawelczyk L, Spaczynski RZ, Dziura J, Duleba AJ. Effects of simvastatin and oral contraceptive agent on polycysticovary syndrome: prospective randomized cross-over trial. J ClinEndocrinol Metab 2007; 92(2): 456-61.
118. Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. The effect ofatorvastatin in patients with polycystic ovary syndrome: a randomizeddouble-blind placebo-controlled study. J Clin Endocrinol Metab 2009; 94(1): 103-8.
119. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovariansyndrome. J Clin Endocrinol Metab 2001; 86: 2453-55.
120. Vlassara H. Advanced glycation in health and disease: role of themodern environment. Ann N Y Acad Sci 2005; 1043: 452-460
121. Kimura Y, Hyogo H, Yamagishi S, et al. Atorvastatin decreasesserum levels of advanced glycation endproducts (AGEs) in nonalcoholicsteatohepatitis (NASH) patients with dyslipidemia: clinicalusefulness of AGEs as a biomarker for the attenuation of NASH. JGastroenterol 2010; 45(7): 750-7.
122. Diamanti-Kandarakis E, Katsikis I, Piperi C, et al. Increased serumAdvanced Glycation End products is a distinct finding in leanwomen with PCOS. Clin Endocrinol (Oxf) 2008; 69(4): 634-41.
123. Diamanti-Kandarakis E, Piperi C, Patsouris E, et al. Immunohistochemicallocalization of advanced glycation end-products (AGEs)and their receptor (RAGE) in polycystic and normal ovaries. HistochemCell Biol. 2007; 127(6): 581-9.
124. Kaya C, Pabuccu R, Cengiz SD, Dünder I. Comparison of theeffects of atorvastatin and simvastatin in women with polycysticovary syndrome: A prospective, randomized study. Exp Clin EndocrinolDiabetes 2010; 118(3): 161-6.
125. Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events inwomen with elevated high-sensitivity C-reactive protein or dyslipidemia:results from the Justification for the Use of Statins in Prevention:An Intervention Trial Evaluating Rosuvastatin (JUPITER)and meta-analysis of women from primary prevention trials. Circulation 2010; 121(9): 1069-77.
126. Banaszewska B, Pawelczyk L, Spaczynski RZ, Duleba AJ. Comparisonof simvastatin and metformin in treatment of polycysticovary syndrome: prospective randomized trial. J Clin Endocrinol Metab. 2009; 94(12): 4938-45.
127. Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. Atorvastatinpretreatment augments the effect of metformin in patients withpolycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2010;72(4): 566-8.
128. Ciampelli M, Leoni F, Lattanzi F, Guido M, Apa R, Lanzone A. Apilot study of the long-term effects of acipimox in polycystic ovariansyndrome. Hum Reprod 2002; 17(3): 647-53.
129. Cussons AJ, Watts GF, Mori TA, Stuckey BG. Omega-3 fatty acidsupplementation decreases liver fat content in polycystic ovarysyndrome: a randomized controlled trial employing proton magneticresonance spectroscopy. J Clin Endocrinol Metab 2009;94(10): 3842-8
130. Hara S, Takahashi T, Amita M, Igarashi H, Kurachi H. Usefulnessof bezafibrate for ovulation induction in clomiphene citrateresistantpolycystic ovary syndrome patients with dyslipidemia: aprospective pilot study of seven cases. Gynecol Obstet Invest 2010; 70(3): 166-72.
131. Zang M, Zuccollo A, Hou X, et al. AMP-activated protein kinase isrequired for the lipid-lowering effect of metformin in insulin resistanthuman HepG2 cells. J Biol Chem 2004; 279: 47898-905.
132. Cleasby ME, Dzamko N, Hegarty BD, Cooney GJ, Kraegen EW, Ye JM. Metformin prevents the development of acute lipid inducedinsulin resistance in the rat through altered hepatic signalingmechanisms. Diabetes 2004; 53: 325-66.
133. Viollet B, Foretz M, Guigas B, et al. Activation of AMP-activatedprotein kinase in the liver: a new strategy for the management ofmetabolic hepatic disorders. Journal of Physiology 2006; 574: 41-53
134. Palomba S, Falbo A, Zullo F, Orio F Jr. Evidence-based and potentialbenefits of metformin in the polycystic ovary syndrome: acomprehensive review. Endocr Rev 2009; 30(1): 1-50.
135. Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeuticeffects of metformin on insulin resistance and hyperandrogenismin polycystic ovary syndrome. Eur J Endocrinol 1998; 138:269-74
136. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L.Incidence and treatment of metabolic syndrome in newly referredwomen with confirmed polycystic ovarian syndrome. Metabolism 2003; 52: 908-15.
137. Romualdi D, De Marinis L, Campagna G, Proto C, Lanzone A, Guido M. Alteration of ghrelin-neuropeptide Y network in obesepatients with polycystic ovary syndrome: role of hyperinsulinism. Clin Endocrinol 2008; 69: 562-567
138. Attia GR, Rainey WE, Carr BR. Metformin directly inhibits androgenproduction in human thecal cells. Fertil Steril 2001; 76: 517-24.
139. Aruna J, Mittal S, Kumar S, Misra R, Dadhwal V, Vimala N. Metformintherapy in women with polycystic ovary syndrome. Int JGynaecol Obstet 2004; 87: 237-41.
140. Banazwenska B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Lipidsin polycystic ovary syndrome: role of hyperinsulinemia and effectsof metformin. Am J Obstet Gynecol 2006; 194: 1266-72
141. Santana LF, de Sá MF, Ferriani RA, de Moura MD, Foss MC, dos Reis RM. Effect of metformin on the clinical and metabolic assessmentof women with polycystic ovary syndrome. Gynecol Endocrinol 2004; 19: 88-96.
142. Ibanez L, Valls C, Potau N, Marcos MV, de Zegher F. Sensitizationto insulin in adolescent girls to normalize hirsutism, hyperandrogenism,oligomenorrhea and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab 2000; 85: 3526-30.
143. Moghetti P, Castello R, Negri C, et al. Metformin effects on clinicalfeatures, endocrine and metabolic profiles, and insulin sensitivityin polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinicalevaluation. J Clin Endocrinol Metab 2000; 85: 139-46.
144. Fleming R, Hopkinson ZE, Wallace AM, Greer IA, Sattar N. Ovarianfunction and metabolic factors in women with oligomenorrheatreated with metformin in a randomized double blind placebocontrolledtrial. J Clin Endocrinol Metab 2002; 87: 569-74.
145. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovarysyndrome: systematic review and meta-analysis. BMJ 2003; 327:951-53
146. Tang T, Glanville J, Hayden CJ, White D, Barth JH, Balen AH. Combined lifestyle modification and metformin in obese patientswith polycystic ovary syndrome. A randomized, placebo controlled,double-blind multicentre study. Hum Reprod 2006; 21: 80-89.
147. Heutling D, Schulz H, Nickel I, et al. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycysticovary syndrome before and after metformin treatment. J Clin Endocrinol Metab 2008; 93(1): 82-90.
148. Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS. The impact of metformin, oral contraceptives and lifestylemodification, on polycystic ovary syndrome in obese adolescentwomen in two randomized, placebo-controlled clinical trials. J ClinEndocrinol Metab 2008; 93(11): 4299-4306.
149. Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, Martínez-Bermejo E, Lasunción MA, Escobar-Morreale HF. Comparisonof ethinyl-estradiol plus cyproterone acetate versus metformineffects on classic metabolic cardiovascular risk factors inwomen with the polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92: 2453-61.
150. Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin oranti-androgen in the treatment of hirsutism in polycystic ovarysyndrome. J Clin Endocrinol Metab 2003; 88: 4116-23.
151. Sahin Y, Unluhizarci K, Yilmazsoy A, Yikilmaz A, Aygen E, Kelestimur F. The effects of metformin on metabolic and cardiovascularrisk factors in non-obese women with polycystic ovarysyndrome. Clin Endocrinol (Oxf) 2007; 67: 904-8.
152. Muniyappa R, Montagnani M, Kon Koh K, Quon M. Cardiovascularactions of insulin. Endocr Rev 2007; 28: 463-91.
153. Davis BJ, Xie Z, Viollet B, Zou MH. Activation of the AM Pactivatedkinase by antidiabetes drug metformin stimulates nitric oxidesynthesis in vivo by promoting the association of heat shock protein90 and endothelial nitric oxide synthase. Diabetes 2006; 55: 496-505.
154. Detaille D, Guigas B, Chauvin C, et al. Metformin prevents highglucoseinduced endothelial cell death through a mitochondrialpermeability transition-dependent process. Diabetes 2005; 54:2179-87.
155. Hattori Y, Suzuki K, Hattori S & Kasai K. Metformin inhibitscytokine-induced nuclear factor kappaB activation via AMP activatedprotein kinase activation in vascular endothelial cells. Hypertension 2006; 47: 1183-88.
156. Huang NL, Chiang SH, Hsueh CH, Liang YJ, Chen YJ, Lai LP. Metformin inhibits TNF-alpha-induced IkappaB kinase phosphorylation,IkappaB-alpha degradation and IL-6 production in endothelialcells through PI3K-dependent AMPK phosphorylation. Int JCardiol 2009; 134: 169-75.
157. Romualdi D, Costantini B, Selvaggi L, et al. Metformin improvesendothelial function in normoinsulinemic PCOS patients: a newprospective. Hum Reprod 2008; 23: 2127-33.
158. Diamanti-Kandarakis E, Alexandraki K, Protogerou A, et al. Metforminadministration improves endothelial function in womenwith polycystic ovary syndrome. Eur J Endocrinol. 2005; 152: 749-56.
159. Orio F Jr, Palomba S, Cascella T, et al. Improvement in endothelialstructure and function after metformin treatment in young normalweightwomen with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab 2005; 90: 6072-76.
160. Topcu S, Tok D, Caliskan M, et al. Metformin therapy improvescoronary microvascular function in patients with polycystic ovarysyndrome and insulin resistance. Clin Endocrinol (Oxf) 2006; 65:75-80.
161. Diamanti-Kandarakis E, Papavasiliou A. Molecular mechanisms ofinsulin resistance in polycystic ovary syndrome. Trends Mol Med 2006; 12: 324-32.
162. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochromeP450c17 alpha activity and serum free testosterone after reductionof insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 335: 617-23.
163. Tosca L, Solnais P, Ferre P, Foufelle F, Dupont J. Metformin inducedstimulation of adenosine 50 monophosphate-activated proteinkinase (PRKA) impairs progesterone secretion in rat granulosacells. Biol Reprod 2006; 75: 342-51.
164. Nestler JE, Jakubowicz DJ. Lean women with polycystic ovarysyndrome respond to insulin reduction with decreases in ovarianP450c17 alpha activity and serum androgens. J Clin EndocrinolMetab 1997; 82: 4075-79.
165. La Marca A, Morgante G, Palumbo M, Cianci A, Petraglia F, DeLeo V. Insulin-lowering treatment reduces aromatase activity in responseto follicle-stimulating hormone in women with polycysticovary syndrome. Fertil Steril 2002; 78: 1234-39.
166. Mansfield R, Galea R, Brincat M, Hole D, Mason H. Metforminhas direct effects on human ovarian steroidogenesis. Fertil Steril 2003; 79: 956-62.
167. Nestler JE. Metformin for the treatment of the polycystic ovarysyndrome. N Engl J Med 2008 358 47-54.
168. Graham D, Green L (2000). Memorandum. Final report: Liverfailure risk with troglitazone (Rezulin) NDA: 20-720. USDHHS, FDA, Center for Drug Evaluation and Research, Bethesda. 19 December
169. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardialinfarction and death from cardiovascular causes. N Engl JMed 2007; 356: 2457-2471.
170. Sharma AM, Staels B. Review: peroxisome proliferator-activatedreceptor gamma and adipose tissue - Understanding obesity-relatedchanges in regulation of lipid and glucose metabolism. J Clin EndocrinolMetab 2007; 92: 386-95.
171. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann InternMed 2001; 134; 61-71.
172. Legro RS, Azziz R, Ehrmann D, Fereshetian AG, O'Keefe M, Ghazzi MN. Minimal response of circulating lipids in women withpolycystic ovary syndrome to improvement in insulin sensitivitywith troglitazone. J Clin Endocrinol Metab 2003; 88: 5137-5144
173. Glueck CJ, Moreira A, Goldenberg N, Sieve L, Wang P. Pioglitazoneand metformin in obese women with polycystic ovary syndromenot optimally responsive to metformin. Hum Reprod 2003; 18: 1618-1625.
174. Romualdi D, Guido M, Ciampelli M, et al. Selective effects ofpioglitazone on insulin and androgen abnormalities in normo- andhyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod 2003; 18: 1210-18.
175. Koo YA, Shin SY, Yoon BK, Choi, D. Pioglitazone for treatingpolycystic ovary syndrome in non-obese women of reproductiveage with different clinical presentations. Gynecol Endocrinol 2007; 23(8): 461-7.
176. Lemay A, Dodin S, Turcot L, Dechene F, Forest JC. Rosiglitazoneand ethinyl estradiol/cyproterone acetate as single and combinedtreatment of overweight women with polycystic ovary syndromeand insulin resistance. Hum Reprod 2006; 21: 121-28
177. Tarkun I, Cetinarslan B, Turemen E, Sahin T, Canturk Z, Komsuoglu B. Effect of rosiglitazone on insulin resistance, C-reactive proteinand endothelial function in non-obese young women withpolycystic ovary syndrome. Eur J Endocrinol 2005; 153: 115-21.
178. Mai K, Andres J, Bobbert T, et al. Rosiglitazone decreases 11betahydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue. Clin Endocrinol (Oxf) 2007; 67: 419-25.
179. Ghazeeri G, Kutteh WH, Bryer-Ash M, Haas D, Ke RW. (). Effectof rosiglitazone on spontaneous and clomiphene citrate-inducedovulation in women with polycystic ovary syndrome. Fertil Steril 2003; 79: 562-66.
180. Paradisi G, Steinberg HO, Shepard MK, Hook G, Baron AD.Troglitazone therapy improves endothelial function to near normallevels in women with polycystic ovary syndrome. J Clin EndocrinolMetab 2003; 88: 576-80.
181. Jensterle M, Sebestjen M, Janez A, Prezelj J, Kocjan T, Keber I, Pfeifer M. Improvement of endothelial function with metforminand rosiglitazone treatment in women with polycystic ovary syndrome. Eur J Endocrinol. 2008; 159(4): 399-406.
182. Naka KK, Kalantaridou SN, Kravariti M, Bechlioulis A, Kazakos N, Calis KA, Makrigiannakis A, Katsouras CS, Chrousos GP, Tsatsoulis A, Michalis LK. Effect of the insulin sensitizers metforminand pioglitazone on endothelial function in young women withpolycystic ovary syndrome: a prospective randomized study. FertilSteril. 2011; 95(1): 203-9
183. Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL et al. Troglitazone improves defects in insulin action,insulin secretion, ovarian steroidogenesis, and fibrinolysis inwomen with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 2108-16.
184. Misugi T, Ozaki K, El BK., Tokuyama O, Honda K, Ishiko O. Insulin lowering agents inhibit synthesis of testosterone in ovariesof DHEA-induced PCOS rats. Gynecol Obstet Invest 2006; 61:208-15.
185. Froment P, Fabre S, Dupont J, et al. Expression and functional roleof peroxisome proliferator-activated receptor gamma in ovarianfolliculogenesis in the sheep. Biol Reprod 2003; 69: 1665-74
186. Kilicdag EB, Bagis T, Zeyneloglu HB, et al. Homocysteine levelsin women with polycystic ovary syndrome treated with metforminversus rosiglitazone: a randomized study. Hum Reprod 2005; 20:894-899.
187. Diamanti-Kandarakis E, Kandaraki E, Christakou C, Panidis D. The effect of pharmaceutical intervention on lipid profile in polycysticovary syndrome. Obes Rev 2009; 10(4): 431-41.
188. Diamanti-Kandarakis E, Mitrakou A, Raptis S, Tolis G, Duleba AJ. The effect of a pure anti-androgen receptor blocker, flutamide, onthe lipid profile in the polycystic ovary syndrome. J Clin Endocrinol Metab 1998; 83: 2699-2705.
189. Ibanez L, Potau N, Marcos MV, de Zegher F. Treatment of hirsutism,hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinismin non-obese, adolescent girls: effect of flutamide. J Clin Endocrinol Metab 2000; 85: 3251-3255.
190. Vrbikova J, Hill M, Dvoráková K, Stanická S, Vondra K, Stárka L. Flutamide suppresses adrenal steroidogenesis but has no effect oninsulin resistance and secretion and lipid levels in overweightwomen with polycystic ovary syndrome. Gynecol Obstet Invest 2004; 58: 36-41.
191. Ibanez L, Valls C, Cabre S, De Zegher F. Flutamide-metforminplus ethinylestradiol-drospirenone for lipolysis and antiatherogenesisin young women with ovarian hyperandrogenism: the key roleof early, low-dose flutamide. J Clin Endocrinol Metab 2004; 89:4716-4720.
192. Gambineri A, Patton L, Vaccina A et al. Treatment with flutamide,metformin, and their combination added to a hypocaloric diet inoverweight-obese women with polycystic ovary syndrome: a randomized,12-month, placebo-controlled study. J Clin Endocrinol Metab. 2006; 91(10): 3970-80.
193. Karakurt F, Sahin I, Güler S, et al. Comparison of the clinical efficacyof flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: A randomisedcontrolled study. Adv Ther 2008; 25(4): 321-328
194. Zulian E, Sartorato P, Benedini S, et al. Spironolactone in thetreatment of polycystic ovary syndrome: effects on clinical features,insulin sensitivity and lipid profile. J Endocrinol Invest 2005; 28: 49-53.